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The human genome is composed of 
approximately three billion base pairs 
and contains large amounts of genetic 
information. Although different types of 
cells share the same DNA, they display 
different phenotypes. It indicates that 
regulated access to the genetic 
information plays an important role in 
understanding cell identity and, thus, 
human development (Sharma et al. 2010, 
Jurkowski et al. 2015). The term 
"epigenetics" was coined by Conrad 
Waddington and defined as “the branch 
of biology which studies the causal 
interactions between genes and their 
products, which bring the phenotype into 
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ABSTRACT 
Epigenetic modifications are responsible for the modulation of gene 
expression without affecting the nucleotide sequence. The observed 
changes in transcriptional activity of genes in tumor tissue compared to 
normal tissue, are often the result of DNA methylation within the promoter 
sequences of these genes. This modification by attaching methyl groups to 
cytosines within CpG islands results in silencing of transcriptional activity 
of the gene, which in the case of tumor suppressor genes is manifested by 
abnormal cell cycle, proliferation and excessive destabilization of the 
repair processes. Further studies of epigenetic modifications will allow a 
better understanding of mechanisms of their action, including the 
interdependence between DNA methylation and activity of proteins crucial 
to the structure of chromatin and gene activity. Wider knowledge of 
epigenetic mechanisms involved in the process of malignant 
transformation and pharmacological regulation of the degree of DNA 
methylation provides an opportunity to improve the therapeutic actions in 
the fight against cancer. 
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being” (Goldberg et al. 2007, Kunwor et 
al. 2015). Initially, this definition 
referred to epigenetics in context of 
embryonic development, however it has 
evolved over time and nowadays, 
epigenetics is described as "the study of 
heritable changes in gene expression that 
occur independent of changes in the 
primary DNA sequence" (Sharma et al. 
2010, Brait & Sidransky 2011). Most of 
these changes occur during 
differentiation and are maintained 
through multiple cell divisions, allowing 
cells to develop distinct identities despite 
having the same genetic information. 
Epigenetic modifications such as 
cytosine methylation, histone post-
translational modifications as well as the 
nucleosome positioning along the DNA, 
mediate heritability of gene expression 
patterns (Goldberg et al. 2007, Carone et 
al. 2010, Greer et al. 2011). The set of 
these modifications, known as the 
epigenome, regulates the accessibility of 
the genetic information to the cellular 
machinery, providing a mechanism for 
cell diversity (Lee & Lee 2012). Failure 
to properly maintain epigenetic marks 
can result in disruption of different 
signaling pathways by their inappropriate 
activation or inhibition, and therefore, 
lead to disease such as cancer. Recent 
studies show that both genetic and 
epigenetic alterations are equally 
important and can contribute to all stages 
of human cancer development (Kresse et 
al. 2012, You & Jones 2012, Marquardt 
et al. 2013). In contrast to genetic 
mutations, epigenetic modifications are 
reversible, which makes them an 
attractive and promising target for cancer 
therapy (Esteller 2008, Khan et al. 2008, 
Sadikovic et al. 2008, Riggins 2014, 
Yang et al. 2014, Kunwor et al. 2015, 
Nakamura et al. 2015). 
 
Methylation patterns in normal cells 
Chromatin is composed of repeated 
structural units, known as nucleosomes, 
which consist of approximately 146 base 
pairs of DNA wrapped around a histone 
protein octamer made up of two copies of 
each of the four histone proteins such as 
H2A, H2B, H3 and H4 (Flis et al. 2007, 
Sharma et al. 2010, Lee & Lee 2012). 
DNA methylation, covalent and non-
covalent histone modifications, non-
coding RNAs including miRNAs are 
epigenetic modifications associated with 
alteration of the dynamics of chromatin 
structure, its accessibility and 
compactness. The distinct patterns of 
these modifications regulate the 
functioning of the genome and the way it 
manifests itself in different types of cells, 
stages of development and various 
diseases, including cancer, and thus 
protect the identity of the cell (Sharma et 
al. 2010). 
DNA methylation is a reversible 
addition of a methyl group (-CH3) to 
either adenine or cytosine bases.  
In mammalian cells, methylation  
occurs at the fifth carbon of the  
cytosine pyrimidine ring within CpG 
dinucleotides that can be concentrated in 
short CpG-rich DNA regions known as 
CpG islands or regions of large repetitive 
sequences, such as retrotransposon 
elements and centromeres (Saxonov et al. 
2006, Flis et al. 2007, Łukasik et al. 
2009, Guz et al. 2010, Sharma et al. 
2010). CpG islands are frequently located 
at the 5' regulatory regions of a gene and 
are associated with approximately 60–
70% of human gene promoters. 
Methylation of the CpG island promoter, 
catalyzed by DNA methyltransferases 
(DNMTs) that use S-adenosyl-L-
methionine as the donor of methyl 
groups, prevents binding of transcription 
factors which results in gene silencing 
(Saxonov et al. 2006, Łukasik et al. 
2009, Guz et al. 2010). DNMT1, often 
referred to as the "maintenance" 
methyltransferase, is one of the three 
active DNA methyltransferases identified 
in mammals. It recognizes and binds to 
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hemimethylated CpG sites generated 
during DNA replication in which the 
parental strand remains methylated, 
unlike the newly synthesized one. In 
order to maintain existing CpG 
methylation patterns, DNMT1 attaches a 
methyl group to the cytosines on the 
daughter strand (Hirasawa et al. 2008). 
Two other methyltransferases, DNMT3A 
and DNMT3B, target previously 
unmethylated cytosines and establish 
DNA methylation patterns early in 
development, and therefore are called de 
novo methyltransferases (Flis et al. 2007, 
Heinz et al. 2007, Łukasik et al. 2009, 
Guz et al. 2010, Sharma et al. 2010, Ficz 
& Gribben 2014, Kunwor et al. 2015). 
The pattern of DNA methylation is 
not only a consequence of attachment of 
methyl groups to cytosine but also DNA 
demethylation (Guz et al. 2010, Tan et al. 
2012, Hill et al. 2014). Demethylation is 
a reaction of removal of the methyl group 
and can be considered as DNA 
replication-dependent and independent 
(Guz et al. 2010, Hill et al. 2014). This 
process requires several steps and the 
first one is oxidation of 5-
methylcytosine (5mC) to generate 5-
hydroxymethylcytosine (5hmC) with the 
participation of Tet proteins. It is 
assumed that the more diverse and stable 
the cell is, the less 5hmC can be 
expected. Hydroxylation of 5mC occurs 
most actively in the zygote and embryo 
stage, when parental methylation pattern 
is erased by Tet3 protein. Tet1 Tet2 
proteins are active during embryogenesis, 
making it possible to maintain an 
adequate level of housekeeping gene 
expression and sufficient number of stem 
cells, inhibiting their differentiation 
(Tahiliani et al. 2009, Globisch et al. 
2010, Tan et al. 2012, Hill et al. 2014). 
During the development of the embryo, 
in which cells divide intensively, 5-
hydroxymethylcytosine is transcribed as 
unmodified cytosine, and therefore is not 
recognized by DNMT1. This process is 
called passive DNA demethylation, 
however can be also described as DNA 
replication-dependent, because it occurs 
when DNMT1 does not methylate newly 
synthesized DNA strand. In consequence, 
the second round of replication, which is 
not accompanied by maintenance 
methylation, results in a completely 
unmethylated DNA (Ficz & Gribben 
2014, Arand et al. 2015). Active DNA 
demethylation plays an important role in 
cells that divide less often and can take 
place in several ways. One of them is 
further oxidation using Tet proteins, first 
to the 5-formylcytosine (5fC) and next to 
5-carboxylcytosine (5caC), which must 
be subjected to decarboxylation. There is 
also the possibility of 5hmC 
glycosylation or deamination to 5-
hydroxymethyluracil. In both cases, the 
modified nucleotide is considered to be 
invalid by the base excision repair system 
(BER) and replaced by cytosine. This is 
the way of CpG islands demethylation, 
usually located near the transcription 
initiation site, to which Tet1-3 proteins 
preferentially bind, preventing their 
secondary methylation (Wu & Zhang 
2011, Tan et al. 2012, Hill et al. 2014). 
In normal cells (Fig. 1), methylation 
usually occurs in repetitive regions 
associated with chromosomal stability, 
non-coding regions as well as in gene 
bodies. Although, the majority of  CpG 
islands located in the promoter regions of 
genes are protected from this epigenetic 
mechanism and remain unmodified 
during the development and in 
differentiated tissues, some of them 
become methylated. The most classic 
examples of CpG island methylation 
during the development, resulting in 
long-term transcriptional silencing, are 
X-chromosome inactivation and gene 
imprinting (Flis et al. 2007, Kiefer 2007, 
Esteller 2008, Illingworth et al. 2008, 
Łukasik et al. 2009, Guz et al. 2010).
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Figure 1. DNA methylation in normal cells. 
DNA methylation in cancer cells  
Hypermethylation of CpG islands and global hypomethylation are characteristic of 
cancer cells (Fig. 2). The low level of methylation in the rest of the genome can induce 
the activation of oncogenes located nearby and too frequent methylation within CpG 
islands - silencing of tumor suppressor genes  (Flis et al. 2007, Łukasik et al. 2009, 
Guz et al. 2010, Sharma et al. 2010, Hansen et al. 2011, Yang et al. 2014, Kunwor et 
al. 2015). 
 
Figure 2. DNA methylation in cancer cells. 
 
In colorectal cancer, the 10-30% 
reduction was observed in the overall 
methylation as well as significant 
reduction in the amount of 5-
methylcytosine in premalignant stages of 
the adenoma (Wilson et al. 2007, Ehrlich 
2009, King et al. 2014). 
Hypomethylation of over 50% was noted 
in the tumors of the chest (Wilson et al. 
2007, Rauch et al. 2008). 
Hypomethylation in tumors of blood 
occurs in chronic lymphocytic leukemia 
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(CLL), whereas in the chronic myeloid 
leukemia (CML) and acute myeloid 
leukemia (AML) and multiple myeloma 
there is only a small change in the pattern 
of DNA methylation (Stach et al. 2003, 
Lyko et al. 2004, Wilson et al. 2007). 
The global demethylation occurs in the 
early stages of tumors of the chest, colon 
and in chronic lymphocytic leukemia. In 
addition, in colorectal cancer 
hypomethylation is present in normal 
tissues adjacent to the tumor. In other 
tumors, eg. hepatocellular carcinoma 
hypomethylation increases with 
advancing stage and histological tumor 
stage (Lin et al. 2001, Wilson et al. 
2007). Hypomethylation of specific 
genes was observed in the tumors of 
colon, pancreas, chest, stomach, prostate 
and in leukemia (Sadikovic et al. 2008). 
Usually, these genes regulate growth, 
encode enzymes important for the 
organism's development, tissue-specific 
genes and oncogenes (Flis et al. 2007, 
Guz et al. 2010, Kunwor et al. 2015). 
The most common regions of 
hypermethylation in different kinds of 
tumors are chromosome 3p, 11p and 17p 
(Rush et al. 2001, Choi et al. 2007, 
Sulewska et al. 2007, Stöcklein et al. 
2008). This phenomenon occurs within 
CpG islands which are normally 
unmethylated in the genome. The most 
important consequence of this event is 
silencing the function of tumor 
suppressor genes, for example promoter 
hypermethylation of p16 gene (INK4A), 
which occurs in many tumors. p16 is an 
inhibitor of cyclin-dependent kinase, 
which negatively regulates cell cycle 
progression from G1 to S phase (Flis et 
al. 2007, Li et al. 2011). Abnormal 
expression leads to disruption of the cell 
cycle and the loss of control, which 
stimulates proliferation and affect tumor 
progression. This phenomenon was noted 
in bladder, nose, throat, pancreas, colon, 
lung cancers as well as in melanomas, 
leukemias and glioblastomas. In the 
carcinogenesis of esophageal 
adenocarcinoma promoter methylation of 
the p16 gene can occur already in the 
metaplasia (Auerkari 2006, Li et al. 
2011). In addition, the repression of 
transcription of another gene, MLH1 
encoding DNA mismatch repair protein, 
increases the frequency of mutations and, 
therefore, the abnormal expression of 
other genes (Tsai & Baylin 2011). 
Hypermethylation profile of 15 cancers 
such as colon, stomach, pancreas, liver, 
kidney, lung, head, neck, breast, ovary, 
bladder, endometrium, brain, lymphoma 
and leukemia was examined. Analysis 
consisted of 3 groups of genes: tumor 
suppressor genes: p16, p15, p14 (cyclin-
dependent kinase inhibitors), p73 (p53-
related protein), APC (adenomatous 
polyposis coli protein) and BRCA1 
(breast cancer type 1 susceptibility 
protein); genes responsible for DNA 
repair or metabolism of xenobiotics: 
hMLH1, GSTP1 (glutathione S-
transferase pi-1), MGMT (O
6
-
methylguanine DNA methyltransferase); 
genes involved in invasion and 
metastasis: CDH1 (cadherin-1), TIMP3 
(metalloproteinase inhibitor 3), DAPK 
(death-associated protein kinase). 
Methylation in at least one gene was 
present in every type of tumor. 
Methylation profiles were dependent on 
both the gene and the tumor. Some 
genes, for example p16, MGMT, DAPK 
were methylated in various types of 
cancer (colon, lung, head, neck, ovary, 
bladder, lymphoma and leukemia) 
(Esteller et al. 2001, Flis et al. 2007). 
Hypermethylation of p14, APC, p16, 
MGMT, hMLH1 occurred in 
gastrointestinal tumors (colon, stomach) 
and GSTP1 in steroid tumors (breast, 
liver, prostate). Another study confirmed 
these reports. Methylation depends on the 
type of cancer for the following genes: 
BRCA1 - breast and ovarian cancer, 
hMLH1 - rectal, endometrial, gastric 
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cancer, p73 and p15 in leukemia (Flis et al. 2007, Esteller 2008). 
Methods of detection and potential 
therapies  
Detection methods must have a high 
sensitivity due to the material from which 
the DNA is isolated, and the specificity 
to distinguish methylation of tumor cells 
from methylation present in normal cells. 
None of the methods is universal and 
during the selection attention should be 
paid to the type, quantity and quality of 
the biological material. The correct 
choice of method should minimize the 
risk of contamination of the sample and 
ensure reproducibility of results (Łukasik 
et al. 2009). The most commonly used 
methods are: REP (restriction enzyme 
PCR), MS-PCR (methylation specyfic 
PCR), BSSCP (bisulfite single-strand 
conformation polymorphism), BGS 
(bisulfite genomic sequencing) 
(Majchrzak & Baer-Dubowska 2009, 
Łukasik et al. 2009). There are also other 
methods: MS-nested PCR, QAMA 
(quantitative analysis of methylated 
alleles), Heavy Methyl. The main 
objective of the analysis is the 
differentiation of methylated and 
unmethylated sequences. This can be 
achieved either by using methylation 
sensitive restriction enzyme or chemical 
modification of DNA by sodium 
bisulphite. Sodium bisulfite deaminates 
cytosine to uracil, also m5C can undergo 
this reaction, however, very slow 
formation of the intermediate product 
significantly limits the speed of the 
process. Defined DNA fragments are 
then subjected to allele-specific PCR 
(MS-PCR), SSCP (BSSCP) or 
sequencing (BGS) (Łukasik et al. 2009). 
DNA methylation pattern of adults is 
tissue specific and relatively stable. It is 
known that it can be changed in the early 
stages of embryonic development, during 
cell differentiation. Significant changes 
in the profile of DNA methylation are 
commonly detected in cancer cells 
(Ogoshi et al. 2011, You & Jones 2012). 
In many tumors it has been shown that 
inactivation of tumor suppressor genes is 
accompanied by hypermethylation of the 
promoter regions. Hypermethylation 
within CpG islands which are normally 
unmethylated in the genome, is a factor 
that inhibits transcription and expression 
of genes (Deaton & Bird 2011). 
Considering that tumor suppressor genes 
are involved in cell differentiation and 
regulation of the cell cycle, apoptosis and 
repair of DNA, the consequences of 
hypermethylation of the promoter 
sequences resulting in silencing genes are 
evident. Therefore, compounds which 
inhibit DNA methylation can play a role 
in tumor therapy (Guz et al. 2010, 
Kunwor et al. 2015).  
The best known inhibitors of DNA 
methyltransferases (DNMTs) are cytidine 
analogues modified in the 5 position of 
the pyrimidine: 5-azacytidine, 5-aza-2'-
deoxycytidine (decitabine) (Flis et al. 
2007, Guz et al. 2010, Kunwor et al. 
2015). The mechanism of the 
pharmacological action of these 
compounds is their conversion in cells to 
deoxynucleotide triphosphates and then 
incorporation into DNA in a place of 
cytosines during replication (Brait & 
Sidransky 2011). This modification is 
recognized by DNMT to which it binds 
covalently, blocking its activity. 
Formation of the enzyme-DNA adducts 
reduces the number of active DNMT 
molecules in the nucleus, which in 
subsequent rounds of replication result in 
passive methylation of DNA, and 
therefore in the reactivation of 
epigenetically silenced genes. Covalent 
binding of DNA methyltransferases may 
be responsible for the cytotoxicity of the 
DNMT inhibitors, especially in high 
doses. Low stability in aqueous solutions 
and high toxicity of azanucleosides 
greatly limits their therapeutic potential 
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(Flis et al. 2007, Guz et al. 2010). 
Another cytidine analogue lacking the 
amino group at C4 of the pyrimidine ring 
is Zebularine, which has a similar 
mechanism of action to azanucleosides. 
Zebularine is a compound less toxic than 
5-azacytidine and decitabine, and more 
stable in aqueous solutions, however, its 
bioavailability after oral administration is 
rather low (Cheng et al. 2003, Guz et al. 
2010, Sharma et al. 2010, Kunwor et al. 
2015). Another group of compounds that 
inhibits DNMTs activity are small 
molecule inhibitors, including 
hydralazine (an antihypertensive action), 
procaine (local anesthetic) or 
procainamide (antiarrhythmic drug). 
Procaine and procainamide are 
derivatives of 4-aminobenzoic acid and 
are capable of annealing to a sequence 
rich in CpG, causing the masking target 
sequences for methyltransferase and thus 
block the binding of the enzyme with 
DNA (Guz et al. 2010, Kunwor et al. 
2015). The group of inhibitors, that are 
not nucleoside analogues, includes the 
compounds directly blocking the activity 
of DNA methyltransferase, such as 
epigallocatechin gallate (EGCG), which 
is considered to be the most active of 
green tea polyphenols and L-tryptophan 
derivative (RG108). The mechanism of 
action of these compounds consists in 
blocking the active center of the enzyme. 
RG108 because of its good fit to the 
active center of DNMT1 and low toxicity 
was an attractive candidate for further 
research on the use of anticancer therapy, 
however it has been noted that RG108 is 
genotoxic (Kunwor et al. 2015). An 
alternative mechanism of DNMT 
inhibition could be the use of antisense 
oligonucleotides directed against the 
DNMT mRNA. Hybridization of an 
antisense oligonucleotide with the 
complementary mRNA may block the 
translation, thus reduce the level of DNA 
methyltransferases (Flis et al. 2007, Guz 
et al. 2010). 
 
Conclusions 
DNA methylation plays an important role 
in the complex and multistep regulation 
of expression of the genes, whose 
promoter regions are rich in CpG 
sequences. The above data indicate that 
the methylation and gene expression are 
processes related to each other by several 
factors, such as the activity of  
DNA methyltransferases factors 
transcriptionally, proteins involved in 
demethylation, protein binding 
methylated DNA. Further studies  
of epigenetic processes will allow  
a better understanding of  
mechanisms of their action,  
including the interdependence between  
DNA methylation and activity of 
proteins crucial to the structure of 
chromatin and gene activity. Wider 
knowledge of epigenetic mechanisms 
involved in the process of malignant 
transformation and pharmacological 
regulation of the degree of DNA 
methylation provides an opportunity to 
improve the therapeutic actions in the 
fight against cancer. 
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Streszczenie 
Modyfikacje epigenetyczne odpowiedzialne są za modulację ekspresji genów bez 
ingerencji w sekwencję nukleotydową. Obserwowane zmiany aktywności 
transkrypcyjnej genów w tkankach nowotworowych w porównaniu do tkanki 
prawidłowej, bardzo często są wynikiem metylacji DNA w obrębie sekwencji 
promotorowych tych genów. Modyfikacja ta poprzez przyłączenie grup metylowych do 
cytozyn wysp CpG skutkuje wyciszeniem aktywności transkrypcyjnej genu, co w 
przypadku genów supresorowych przejawia się zaburzeniami cyklu komórkowego, 
nadmierną proliferacją i destabilizacją procesów naprawczych. Dalsze badania nad 
modyfikacjami epigenetycznymi pozwolą na lepsze zrozumienie mechanizmów ich 
działania, w tym zależności pomiędzy metylacją DNA, a aktywnością białek  
decydujących o strukturze chromatyny i aktywności genów. Poszerzanie wiedzy na 
temat epigenetycznych mechanizmów biorących udział w procesie transformacji 
nowotworowej i farmakologicznej regulacji stopnia metylacji DNA może stanowić 
okazję do poprawy działań terapeutycznych w walce z nowotworem.  
 
